rs2078371 — TSPAN2

TSPAN2/NGF Locus — One of the Strongest Migraine Risk Signals in the Genome

On chromosome 1p13, two genes sit in close proximity: TSPAN2 (tetraspanin-2, a membrane scaffold protein) and NGF (nerve growth factor, a neurotrophin critical for the development and sensitization of pain-sensing neurons). A regulatory variant between them — rs2078371 — carries one of the largest single-SNP effect sizes for migraine susceptibility ever identified, ranking 3rd in effect magnitude among 123 loci in the largest migraine genome-wide association study conducted to date¹¹ 3rd in effect magnitude among 123 loci in the largest migraine genome-wide association study conducted to date
Hautakangas et al. 2022 — 102,084 migraine cases, 771,257 controls, Nature Genetics.

The Mechanism

The C allele at rs2078371 sits in the intergenic region between TSPAN2 and NGF and is annotated as a downstream regulatory variant near LINC01765, a long non-coding RNA in this locus. The precise molecular mechanism remains under investigation, but the most compelling biological model points to NGF (nerve growth factor)²² NGF (nerve growth factor)
a secreted neurotrophin that binds TrkA receptors on small-diameter trigeminal sensory neurons, upregulating TRPV1, TRPA1, and Nav1.8 — the ion channels that amplify pain signals during migraine. When NGF is overexpressed or its signalling is dysregulated, trigeminal afferents become hyperexcitable — a state known as peripheral sensitization, in which normally sub-threshold stimuli (light, sound, head movement) trigger pain.

TSPAN2 is a tetraspanin scaffold protein expressed in oligodendrocytes and in endothelial cells. It organizes cell-surface signalling complexes and may influence the local vascular and neuronal environment of the meninges, the pain-sensitive membranes surrounding the brain. Whether the locus effect is mediated through NGF expression, through TSPAN2 function in meningeal cells, or through the LINC01765 non-coding RNA regulating one or both genes is not yet resolved. The GWAS signal pointing to rs2078371 as a tag variant does not identify the causal allele or the gene it acts on — it marks a chromosomal region where one or more regulatory variants alter migraine susceptibility through this cluster of interacting genes.

The biological interpretation is strongly supported by the clinical observation that the effect is larger in migraine without aura (MO)³³ migraine without aura (MO)
the most common migraine subtype, affecting ~75% of migraine sufferers; it lacks the visual/neurological aura that precedes migraine with aura and is thought to have a larger peripheral sensitization component than in migraine with aura. Peripheral sensitization — the NGF-mediated mechanism — is disproportionately implicated in MO pathophysiology, in contrast with the cortical spreading depression that drives aura.

The Evidence

The genetic evidence is robust across three independent large-scale GWAS:

Hautakangas et al. 2022⁴⁴ Hautakangas et al. 2022
Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nature Genetics. is the most definitive study. Among 123 migraine loci identified across more than 873,000 individuals, rs2078371-C has OR=1.112 and P=6×10⁻⁴² — the 3rd strongest effect size in the entire study. The subtype analysis found the signal was driven primarily by migraine without aura, where OR was larger, directly implicating the peripheral/trigeminal sensitization pathway.

Anttila et al. 2013⁵⁵ Anttila et al. 2013
Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nature Genetics. established the TSPAN2 region at chromosome 1p13 as one of five newly discovered migraine loci in 23,285 cases, providing the first genome-wide-significant evidence for this chromosomal region. Gormley et al. 2016⁶⁶ Gormley et al. 2016
Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature Genetics. confirmed the signal in a much larger meta-analysis, cementing the locus as one of the most reliably replicated in migraine genetics.

At the gene level, Coskun et al. 2016⁷⁷ Coskun et al. 2016
Association of BDNF and NGF gene polymorphisms with susceptibility to migraine. Neuropsychiatr Dis Treat. showed that NGF coding variants (rs6330 T allele, OR~1.6 vs controls) are themselves associated with migraine risk, providing direct evidence that NGF protein variation influences migraine biology and making the NGF gene a plausible causal mediator of the GWAS signal at rs2078371.

Practical Actions

Migraine management for C allele carriers is dominated by reducing triggers that amplify peripheral sensitization — the mechanism the locus implicates. Three interventions have specific relevance:

Anti-NGF pharmacology is the most mechanistically targeted approach. Anti-NGF monoclonal antibodies (tanezumab, fasinumab) have been studied extensively for pain conditions driven by peripheral sensitization and have been tested in migraine prevention contexts. While none are yet approved specifically for migraine, the biological logic is direct: if elevated NGF activity at this locus drives trigeminal hyperexcitability, dampening NGF signalling addresses the root mechanism. CGRP-pathway treatments (erenumab, fremanezumab, galcanezumab — all approved for migraine prevention) act downstream of the same trigeminal sensitization cascade, making them especially relevant for the MO-predominant mechanism this locus represents.

Trigger mapping and early abortive treatment are behavioural interventions with strong evidence specifically for MO patients with a high peripheral sensitization component — the subtype this variant most strongly predicts. Cutaneous allodynia (scalp tenderness during migraine) is a clinical marker of peripheral sensitization; carriers experiencing it should treat attacks early with triptans before central sensitization develops, since triptans lose efficacy once central sensitization is established.

Interactions

The rs6330 variant in the NGF coding region is a related SNP in the same gene. Carriers of both rs2078371-C (GWAS regulatory signal) and rs6330-T (NGF coding variant associated with migraine with aura) represent compound risk at the same biological locus, though these are independent associations. The combination has not been formally studied in joint analysis.

rs11172113 (near SLC2A9) and rs10166942 (near TRPM8) are other migraine GWAS loci with distinct mechanisms (ion channel and metabolic pathways) that may interact additively with TSPAN2/NGF locus risk. Compound actions across multiple migraine-risk loci should be considered when users carry multiple high-risk genotypes.